Cetera Investment Advisers
BLRX

Cetera Investment Advisers’s BioLineRX BLRX Stock Holding History

Cetera Investment Advisers’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,004
Closed -$43K – 3793
2024
Q3 		$43K Buy
2,004
+212
+12% +$5.82K ﹤0.01% 3611
2024
Q2 		$40.8K Buy
1,792
+1,341
+297% +$36K ﹤0.01% 3608
2024
Q1 		$20.2K Buy
451
+179
+66% +$8.98K ﹤0.01% 3630
2023
Q4 		$17.1K Sell
272
-100
-27% -$6.19K ﹤0.01% 2198
2023
Q3 		$27K Buy
372
+15
+4% +$1.01K ﹤0.01% 2150
2023
Q2 		$22.8K Sell
357
-143
-29% -$7.92K ﹤0.01% 2153
2023
Q1 		$17.7K Buy
+500
New +$13.1K ﹤0.01% 2126

Other funds holding BLRX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Cetera Investment Advisers's BLRX Position: Q4 2024 in Review

Cetera Investment Advisers sold out of BioLineRX (BLRX) in Q4 2024, closing a stake of 2,004 shares — an estimated $43K sold.

Cetera Investment Advisers first reported a position in BLRX in Q1 2023 and held it in 7 quarters. The position peaked at $43K in Q3 2024. 31 funds tracked by Wall St. Rank hold BLRX as of Q4 2024.

  • Cetera Investment Advisers reported no remaining BioLineRX position as of Q4 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 2,004 BioLineRX shares in Q4 2024, an estimated $43K.
  • Cetera Investment Advisers first reported a position in BioLineRX in Q1 2023 and held it in 7 quarters.
  • Cetera Investment Advisers's BioLineRX position peaked at $43K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held BioLineRX as of Q4 2024.

Based on Cetera Investment Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.